Hsbc Holdings PLC Buys New Holdings in BioNTech SE Sponsored ADR $BNTX

Hsbc Holdings PLC purchased a new position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 52,279 shares of the company’s stock, valued at approximately $4,969,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Royal Bank of Canada grew its stake in BioNTech by 95.9% in the first quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock valued at $653,000 after acquiring an additional 3,514 shares during the period. NewEdge Advisors LLC acquired a new position in shares of BioNTech during the first quarter worth approximately $167,000. Russell Investments Group Ltd. raised its position in shares of BioNTech by 368,800.0% during the second quarter. Russell Investments Group Ltd. now owns 11,067 shares of the company’s stock worth $1,178,000 after purchasing an additional 11,064 shares during the period. Natixis bought a new position in shares of BioNTech in the 2nd quarter worth $985,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in shares of BioNTech by 2.9% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 492,045 shares of the company’s stock worth $52,416,000 after purchasing an additional 13,788 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

Insider Activity

In other news, COO Sierk Poetting sold 50,000 shares of the stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total value of $5,528,000.00. Following the completion of the sale, the chief operating officer owned 399,387 shares in the company, valued at $44,156,226.72. This represents a 11.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is currently owned by insiders.

BioNTech Trading Up 1.4%

Shares of BioNTech stock opened at $91.22 on Friday. The stock has a fifty day simple moving average of $93.96 and a 200 day simple moving average of $97.92. BioNTech SE Sponsored ADR has a 12-month low of $79.52 and a 12-month high of $124.00. The company has a market capitalization of $23.07 billion, a P/E ratio of -15.51 and a beta of 1.32. The company has a current ratio of 8.80, a quick ratio of 8.74 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. The company had revenue of $1.06 billion during the quarter. On average, sell-side analysts anticipate that BioNTech SE Sponsored ADR will post -5.67 earnings per share for the current fiscal year.

BioNTech declared that its board has authorized a stock repurchase program on Thursday, May 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 4.2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

Analysts Set New Price Targets

Several analysts recently issued reports on BNTX shares. HC Wainwright reissued a “buy” rating and issued a $130.00 price target on shares of BioNTech in a research report on Monday, April 27th. Wall Street Zen lowered shares of BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. UBS Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $117.00 to $135.00 in a report on Wednesday, May 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research report on Wednesday, April 8th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of BioNTech in a report on Friday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, BioNTech presently has an average rating of “Moderate Buy” and a consensus price target of $129.56.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.